VEA
BDTX icon

Virtus ETF Advisers’s Black Diamond Therapeutics BDTX Stock Holding History

Virtus ETF Advisers’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,600
Closed -$140K – 381
2021
Q3 		$140K Sell
16,600
-862
-5% -$8.51K 0.06% 351
2021
Q2 		$213K Buy
17,462
+8,706
+99% +$172K 0.09% 298
2021
Q1 		$212K Buy
8,756
+153
+2% +$4.13K 0.09% 317
2020
Q4 		$276K Sell
8,603
-317
-4% -$10.4K 0.11% 261
2020
Q3 		$270K Sell
8,920
-1,214
-12% -$36.9K 0.14% 248
2020
Q2 		$427K Buy
+10,134
New +$373K 0.2% 174

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's BDTX Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 16,600 shares — an estimated $140K sold.

Virtus ETF Advisers first reported a position in BDTX in Q2 2020 and held it in 6 quarters. The position peaked at $427K in Q2 2020. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 16,600 Black Diamond Therapeutics shares in Q4 2021, an estimated $140K.
  • Virtus ETF Advisers first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 6 quarters.
  • Virtus ETF Advisers's Black Diamond Therapeutics position peaked at $427K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.